Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation.
We report a case of early-onset acute Guillain-Barre syndrome associated with reactivation of Epstein-Barr virus (EBV) infection after nonmyeloablative stem cell transplantation (NST). Reactivation of EBV infection preceded disease onset, and the virus load increased concomitantly with disease progression (doubling time, 2.7 days). This case raises concern about the expanding scope of manifestations associated with reactivation of EBV infection after NST.
Bitan
Menachem
M
Department of Bone Marrow Transplantation and Cancer Chemotherapy, Hadassah University Hospital, Jerusalem, Israel. mbitan@hadassah.org.il
Or
Reuven
R
Shapira
Michael Y
MY
Mador
Nurith
N
Resnick
Igor B
IB
Saleh
Niveen
N
Weinberger
Klaus M
KM
Samuel
Simcha
S
Schechter
Esther
E
Slavin
Shimon
S
Wolf
Dana G
DG
D000961:Antilymphocyte Serum / Q000009:adverse effects; D002066:Busulfan / Q000009:adverse effects; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000821:virology; D020275:Guillain-Barre Syndrome / Q000209:etiology* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012493:Samarium / Q000009:adverse effects; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives; D014775:Virus Activation / Q000187:drug effects*
D000961:Antilymphocyte Serum; D012493:Samarium; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine